Merck Just Sold Off Its Moderna Shares for a Huge Gain. Should You?

Merck Just Sold Off Its Moderna Shares for a Huge Gain. Should You?
Keith Speights, The Motley Fool

Practically everything is going right for Moderna (NASDAQ: MRNA) these days. The biotech announced surprisingly positive efficacy results for its COVID-19 vaccine candidate mRNA-1273, and it has filed for Emergency Use Authorization (EUA) in the U.S. and approval in Europe. Moderna's shares have understandably skyrocketed.